Showing results (191-200 of 232) with videos related to
Sort By:
Pageof 24
Cancer Chemotherapy and Pharmacology|October 26, 2010
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumorsCarlos Castaneda, Kellen L Meadows, Roxanne Truax, et al.Blood|April 15, 1997
Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemiaD Pajkrt, T van der Poll, M Levi, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 25, 2001
Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidaseN E Austin, S J Baldwin, L Cutler, et al.The New England Journal of Medicine|February 10, 2021
Phase 3 Trials of Tirbanibulin Ointment for Actinic KeratosisAndrew Blauvelt, Steven Kempers, Edward Lain, et al.The American Journal of Psychiatry|October 1, 1989
A basic residency curriculum concerning the chronically mentally illL R Faulkner, D L Cutler, D D Krohn, et al.Pharmaceutics|October 27, 2022
Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I ResultsJin-Bon Hong, Po-Yuan Wu, Albert Qin, et al.European Journal of Cancer (Oxford, England : 1990)|November 21, 2002
Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumoursA Awada, F A L M Eskens, M Piccart, et al.International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjectsXia Chen, Teddy Kosoglou, Paul Statkevich, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumorsF A Eskens, A Awada, D L Cutler, et al.British Journal of Clinical Pharmacology|September 19, 2002
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatinTeddy Kosoglou, Ingo Meyer, Enrico P Veltri, et al.Pageof 24